Develops and sells MRI-guided ultrasound systems and single-use devices that help physicians treat prostate disease, uterine fibroids and other diseased tissue.
10-K for FY2025, filed Mar 5, 2026We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free…View ↗
Our Sonalleve system is CE Marked in the EU for ablation of uterine fibroids and adenomyotic tissue, palliative relief of pain associated…View ↗
Our business model consists of two components - sales of capital equipment and recurring non-capital equipment which includes one-time-use…View ↗
The larger revenue stream comes from one-time-use devices and extended-warranty services: device sales are counted at shipment, while warranty services are counted over the coverage period. Customers buy systems, installation and training at shipment.
10-K for FY2025, filed Mar 5, 2026
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$16.1M
10-K for FY2025, filed Mar 5, 2026
$16.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Recurring - non-capital
|
60% |
Recurring - non-capital, FY2025
$9.7M Sources
|
|
|
Capital equipment
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
40% |
Capital equipment, FY2025
$6.4M Sources
|
Sold outright |
The systems are used by physicians with customers’ existing MRI scanners; capital equipment sales also include distributors, and collaborative partners assist with sales, marketing or distribution.
10-K for FY2025, filed Mar 5, 2026We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free…View ↗
Capital equipment revenue consists of the sale of capital equipment including installation and training amounts, which includes sales to…View ↗
We rely on collaborative partners to assist in the sales and marketing and/or distribution of our approved products.View ↗
No. It lost $42.6M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$41.3MView ↗
10-K for FY2025, filed Mar 5, 2026
−$42.6MView ↗
10-K for FY2025, filed Mar 5, 2026
−$38.4MView ↗
10-Q for Q2 FY2026, filed Aug 6, 2026
−$9.5MView ↗
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
8-K, filed Aug 17, 2026
On August 14, 2026, Profound Medical Corp. (the “Company” or “Profound Medical”) announced that Matthew Sobczyk has been appointed by the…View ↗
Loading...